Paper Review Records
All Paper Review Records
19 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
Treatment outcomes and quality of life with palbociclib in patients with advanced breast cancer who also have other medical conditions: a plain language summary of findings from POLARIS
Debu Tripathy; Joanne L. Blum; Meghan S. Karuturi; Steven McCune; Sobha Kurian; Mehdi M. Moezi; Daniel M. Anderson; Yan Ji; Timothy J. Pluard; John Migas; Shailendra Lakhanpal; Erin Jepsen; Yao Wang; Monica Z. Montelongo; Zhe Zhang; Joseph C. Cappelleri; Eric Gauthier; Gabrielle B. RocqueShow moreShow less
1. aDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2. bDepartment of Oncology, Baylor-Sammons Cancer Center, Texas Oncology, US Oncology, Dallas, TX, USA; 3. cWilliam S. Gibbons Cancer Research Institute, Northwest Georgia Oncology Centers Wellstar, Marietta, GA, USA; 4. dHematology/Oncology, West Virginia University Cancer Institute, Morgantown, WV, USA; 5. eMedical Oncology, Cancer Specialists of North Florida, Fleming Island, FL, USA; 6. fOncology & Hematology, Health Partners Institute, Saint Paul, MN, USA; 7. gHealth Partners Institute, Saint Paul, MN, USA; 8. hSaint Luke’s Cancer Institute, Kansas City, MO, USA; 9. iMid-Illinois Hematology & Oncology Associates Ltd, Normal, IL, USA; 10. jSaint Vincent’s Birmingham, Birmingham, AL, USA; 11. kNovant Health, Winston-Salem, NC, USA; 12. lOncology Medical Group, Pfizer Inc, New York, NY, USA; 13. mBiostatistics and Medical Writing, ICON Commercialization and Outcomes, ICON Plc., Blue Bell, PA, USA; 14. nOncology Clinical Statistics, Pfizer Inc, San Diego, CA, USA; 15. oStatistical Research and Data Science Center, Pfizer Inc, Groton, CT, USA; 16. pGlobal Medical Affairs, Pfizer Inc, San Francisco, CA, USA; 17. qDivision of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USAShow moreShow less
Study design of the phase III ADELA trial of elacestrant with or without everolimus in ESR1 -mutated ER+/HER2– advanced breast cancer after progression on endocrine therapy plus a CDK4/6 inhibitor
José Manuel Pérez-García; Antonio Llombart-Cussac; Elena López-Miranda; Alfonso Cortes; Isabel Garcia; Elena Galve-Calvo; Manuel Ruiz-Borrego; Alba Cochs; Antonia Perelló-Martorell; Serafin Morales; Laia Boronat Ruiz; Sara Marín-Liébana; Cristina Saavedra; Isabel Blancas; Carmen Hinojo; Mariana López Flores; Sylvain Ladoire; Peter Schmid; Gilles Freyer; Rui Rui Zhang; Daniel Alcalá-López; Juliana Carvalho-Santos; Olga Boix; Carlos H. Barrios; Giuseppe Curigliano; Rupert Bartsch; Anne Clair Hardy Bessard; Tomer Wasserman; Javier CortésShow moreShow less
1. Barcelona (Spain); 2. Quiron Group; 3. Medical Oncology Department, Hospital Arnau de Vilanova, FISABIO; 4. Universidad Cardenal Herrera-CEU; 5. Hospital Universitario Ramón y Cajal (IRYCIS); 6. Department of Radiology, Hospital Clínic i Provincial de Barcelona; 7. Medical Oncology Department, Hospital Universitario de Basurto; 8. Virgen del Rocío University Hospital; 9. Hospital Universitari Sant Joan de Reus; 10. Medical Oncology Department, Hospital Universitari Son Espases; 11. Medical Oncology Department, Hospital Universitario Arnau de Vilanova de Lleida; 12. Medical Oncology Department, Institut Català d’ Oncologia Badalona (ICO); 13. Hospital Beata Maria Ana; 14. Medical Oncology Department, Hospital Universitario San Cecilio Clinic; 15. Granada University; 16. Translational and Integrative Oncology, Instituto de Investigación Biosanitaria de Granada (ibs.Granada); 17. Medical Oncology Department, Hospital Universitario Marqués de Valdecilla – Instituto de Investigación Valdecilla (IDIVAL); 18. Medical Oncology Department, Hospital Universitario de León; 19. Centre Georges-François Leclerc; 20. Barts Cancer Institute, Queen Mary University of London, London; 21. Medical Oncology Department, Barts Hospital NHS Trust; 22. Medical Oncology Department, Centre Hospitalier Lyon-Sud Hospices Civils de Lyon; 23. Oncology Research Center, Latin American Cooperative Oncology Group (LACOG) - Porto Alegre, Brazil Oncoclinicas Group; 24. University of Milano; 25. Medical University of Vienna; 26. CARIO-HPCA, UNICANCER; 27. Global Medical Affairs, Menarini Group; 28. Department of MedicineShow moreShow less
Falcon – multicancer early detection (MCED) real-world evidence (RWE) registry
Ronan J. Kelly; Peter J. Hulick; Henry Mark Dunnenberger; Mindi Styn; Jessica Profato-Partlow; Deb Kettner-Sieber; Michelle A. Beidelschies; Sara Jackson; Pratima R. Bakshi; William T. Christensen; Jahnave Gudaru; Akira S. Numajiri; Khang N. Tran; Vijay Parthasarathy; Tomasz M. BeerShow moreShow less
1. Baylor University Medical Center; 2. Mark R. Neaman Center for Personalized Medicine, Endeavor Health; 3. Abbott Cancer Diagnostics; 4. Baylor Scott & White MedProvider; 5. Baylor Scott & White Family Medical Center-Riverside; 6. Baylor Scott & White Primary Care at the StarShow moreShow less
Protocol for a multicenter prospective phase II trial of adjuvant tislelizumab combined with S-1 in subjects with residual primary lesions and node-negative esophageal squamous cell carcinoma (PPIO-008)
Ying-Jian Wang; Xv Chen; Xian-Feng Xie; Chang-Feng Li; Tao Bao; Xian-Dong He; Kun-Kun Li; Xiang-Shu Pu; Yan He; Wei GuoShow moreShow less
1. Army Medical Center of People’s Liberation Amry of China (Daping Hospital)Show moreShow less
A plain language summary of results from the NeoADAURA study: treatment with osimertinib before surgery for patients with EGFR-mutated non-small cell lung cancer that can be surgically removed
Jianxing He; Walter Weder; Ke-Neng Chen; Maximilian J. Hochmair; Jin-Yuan Shih; Sung Yong Lee; Kang-Yun Lee; Viet Nhung Nguyen; Somcharoen Saeteng; Lunxu Liu; Ligang Xing; Nguyen Hoang Gia; Shuji Murakami; Yongtao Han; María Paz Saavedra; Seong Hoon Yoon; Carlos H.A. Teixeira; Carles Escriu; Alex Martinez-Martí; Collin M. Blakely; Yasushi Yatabe; Sanja Dacic; Yuri Rukazenkov; Xiangning Huang; Anupriya Dayal; Jamie E. Chaft; for the NeoADAURA InvestigatorsShow moreShow less
1. aDepartment of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease & National Clinical Research Centre for Respiratory Disease, Guangzhou, China; 2. bDepartment of Thoracic Surgery, University of Zurich, Thoracic Surgery, Clinic Bethanien, Zurich, Switzerland; 3. cState Key Laboratory of Molecular Oncology, Beijing Key Laboratory of Carcinogenesis and Translational Research, The First Department of Thoracic Surgery, Peking University Cancer Hospital & Institute, Beijing, China; 4. dKarl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria; 5. eDepartment of Respiratory and Critical Care Medicine, Klinik Floridsdorf, Vienna Healthcare Group, Vienna, Austria; 6. fDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; 7. gDivision of Pulmonary Medicine, Department of Internal Medicine, Korea University Guro Hospital, Seoul, Republic of Korea; 8. hDivision of Pulmonary Medicine, Department of Internal Medicine, Shuang-Ho Hospital, Taipei Medical University, Taipei, Taiwan; 9. iVietnam National Lung Hospital, Faculty of Medicine, UMP, VNU, Hanoi, Vietnam; 10. jDepartment of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; 11. kDepartment of Thoracic Surgery, West China Hospital of Sichuan University, Chengdu, China; 12. lDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China; 13. mDepartment of Medical Oncology, Hanoi Oncology Hospital, Hanoi, Vietnam; 14. nDepartment of Thoracic Oncology, Kanagawa Cancer Canter, Yokohama, Japan; 15. oDepartment of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China; 16. pOrlandi Oncología, Santiago, Chile; 17. qDepartment of Internal Medicine, Pusan National University, School of Medicine, and Yangsan Hospital, Yangsan, Republic of Korea; 18. rClinical Oncology Department, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil; 19. sDepartment of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK; 20. tDepartment of Medical Oncology, Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK; 21. uDepartment of Medical Oncology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Barcelona, Spain; 22. vDepartment of Medicine, University of California, San Francisco, CA, USA; 23. wHelen Diller Comprehensive Cancer Center, University of California, San Francisco, CA, USA; 24. xDepartment of Diagnostic Pathology, National Cancer Center, Tokyo, Japan; 25. yDepartment of Pathology, Yale School of Medicine, New Haven, CT, USA; 26. zLate-stage Development, Oncology R&D, AstraZeneca, Cambridge, UK; 27. aaBiometrics, Late-stage Development, Oncology R&D, AstraZeneca, Cambridge, UK; 28. bbLate-stage Development, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA; 29. ccThoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 30. ddDepartment of Medicine, Weill Cornell Medical College, New York, NY, USAShow moreShow less
Plain language summary of the ReNeu study: a study of mirdametinib for adults and children with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas
Angela Hirbe; Christopher L Moertel; Dusica Babovic-Vuksanovic; Claas Röhl; Kim Bischoff; Kate Kelts; Abraham J Langseth; Michael D Weber; Beverly Oberlander; Adli Wunderlich; Julie Jared; Timothy R GershonShow moreShow less
1. aDivision of Oncology, Washington University, St. Louis, MO, USA; 2. bDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA; 3. cMayo Clinic, Rochester, MN, USA; 4. dNF Patients United – Global Network of NF Patient Organisations, The Netherlands; 5. eNeurofibromatosis Network, IL, USA; 6. fChildren’s Tumor Foundation, NY, USA; 7. gSpringWorks Therapeutics, Inc, a healthcare company of Merck KGaA, Darmstadt, Germany; Stamford, CT, USA; 8. hPatient and Caregiver Author; 9. iPatient Author; 10. jCaregiver Author; 11. kDepartment of Pediatrics, Emory University, Atlanta, GA, USAShow moreShow less
FAQ
How long does Future Oncology take to review a manuscript?
As of 2026-11-19, CrushSCI has 19 complete review records for Future Oncology. The fastest paper went from submission to acceptance in 53 days (Study design of the phase III ADELA trial of elacestrant with or without everolimus in ESR1 -mutated ER+/HER2– advanced breast cancer after progression on endocrine therapy plus a CDK4/6 inhibitor, received 2026-08-28, accepted 2026-10-20); the slowest took 274 days. The average is 141.1 days and the median is 125 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
